(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
Vaxcyte's earnings in 2025 is -$657,201,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2025 to be -$677,466,092, with the lowest PCVX earnings forecast at -$764,597,301, and the highest PCVX earnings forecast at -$596,539,840. On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$780,227,509, with the lowest PCVX earnings forecast at -$1,091,732,052, and the highest PCVX earnings forecast at -$542,933,726.
In 2027, PCVX is forecast to generate -$833,414,723 in earnings, with the lowest earnings forecast at -$928,806,117 and the highest earnings forecast at -$556,678,883.